Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.52 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.42 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18844940 | 0.86 | GRIN2D (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL20657642 | 0.70 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1075539 | 0.69 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1674923 | 0.69 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21026936 | 0.68 | GRIN2D (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6517328 | 0.67 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL26605080 | 0.67 | GRIN2D (0.94) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11437112 | 0.65 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11150892 | 0.65 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL26080212 | 0.65 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230284516-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230140064-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-04 | — | — | US | disclosed |
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2017-05-11 | — | — | US | disclosed |
| EP-2802553-B1 | METHOD FOR PRODUCING SECONDARY AMINES IN THE LIQUID PHASE | BASF SE (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2802553-B1 | METHOD FOR PRODUCING SECONDARY AMINES IN THE LIQUID PHASE | BASF SE (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9000218-B2 | Process for preparing secondary amines in the liquid phase | BASF SE (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000218-B2 | Process for preparing secondary amines in the liquid phase | BASF SE (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20130178656-A1 | PROCESS FOR PREPARING SECONDARY AMINES IN THE LIQUID PHASE | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178656-A1 | PROCESS FOR PREPARING SECONDARY AMINES IN THE LIQUID PHASE | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230284516-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXER1, LBR, C1R | GRIN2D 450/4885GRIN3B 1889/4885GRIN1 736/4885 |
| US-20130178656-A1 | PROCESS FOR PREPARING SECONDARY AMINES IN THE LIQUID PHASE | ADH1A, ADH5, ADH1C | GRIN2D 2083/4885GRIN3B 2736/4885GRIN1 3307/4885 |
| US-20170128489-A1 | ORGANO-TRANSITION METAL COMPLEXES FOR THE TREATMENT OF VIRAL INFECTIONS | HVCN1, TRPM8, TRPM2 | GRIN2D 1193/4885GRIN3B 254/4885GRIN1 390/4885 |
| US-20230140064-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, CCND3 | GRIN2D 106/4885GRIN3B 1751/4885GRIN1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.